

REVIEW

High-rate breakthrough cancer pain and tumour characteristics – literature review and case series

Arturo Cuomo¹, Anastasios Boutis², Francesca Colonese³, Davide Nocerino¹

¹IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy; ²First Department of Clinical Oncology, Theagenio Hospital, Thessaloniki, Greece; ³Department Medical Oncology-ASST-Monza Ospedale San Gerardo, Monza, Italy

Abstract

Cancer pain requires careful comprehensive patient evaluation and an appropriate and personalized clinical approach by a trained multidisciplinary team. The proper assessment of breakthrough cancer pain (BTcP) is part of an all-inclusive multidimensional evaluation of the patient. The aim of this narrative review is to explore the relationship between high-rate BTcP, which strongly impacts health-related quality of life and tumour characteristics, in the face of novel approaches that should provide guidance for future clinical practice. The presentation of short, emblematic clinical reports also promotes knowledge of BTcP, which, despite the availability of numerous therapeutic approaches, remains underdiagnosed and undertreated.

This article is part of the *Management of breakthrough cancer pain* Special Issue: https://www.drugsincontext.com/special_issues/management-of-breakthrough-cancer-pain

Keywords: breakthrough pain, breast cancer, cancer pain, lung cancer, neuropathic pain, pancreatic cancer.

Citation

Cuomo A, Boutis A, Colonese F, Nocerino D. High-rate breakthrough cancer pain and tumour characteristics – literature review and case series. *Drugs Context*. 2023;12:2022-11-1. <https://doi.org/10.7573/dic.2022-11-1>

Introduction

Pain is a very personal experience that feels different for everyone^{1,2} and can affect physical and emotional functions differently, with a global impact on the quality of life (QoL).³⁻⁶ Pain is one of the most common symptoms in patients with cancer⁷ and can be caused by several factors, including the tumour itself, treatment or a combination of both. There is evidence that moderate-to-severe pain intensity^{8,9} and breakthrough cancer pain (BTcP)¹⁰⁻¹³ correlate with worse outcomes and greater impairment of overall QoL in patients with cancer.

The 2009 definition of BTcP by the Scientific Committee Working Group of the Association for Palliative Medicine of Great Britain and Ireland¹⁴ remains valid and states that BTcP is an acute, transient exacerbation of severe pain that occurs spontaneously or due to a specific trigger in a patient whose baseline cancer pain is stable and controlled most of the time. Usually, BTcP is described as sudden, acute pain with high intensity that is clearly distinguishable from background pain. Most BTcP episodes peak in intensity within a few minutes and last for 30–60

minutes.^{12,15-17} Idiopathic or spontaneous BTcP occurs in the absence of a relationship to any specific, recognizable cause, whereas incident pain can be volitional if triggered by a voluntary act (e.g. walking, weightbearing, food/liquid ingestion, and changes in sleeping position) or non-volitional if related to an involuntary act (e.g. coughing, chewing, swallowing, vomiting, intestinal peristalsis, and bladder spasm).^{14,16,18-20} In their observational study of 1000 patients, Davies et al. stated that 44% of patients with cancer reported incident pain, whereas 41.5% reported spontaneous pain and 14.5% both types.¹² In the Italian Oncologic Pain multiSetting Multicentric Survey (IOPS-MS) study of 4,016 patients with cancer, BTcP was reported to be idiopathic by 69.5%.²¹

Procedural breakthrough pain is considered a particular type of predictable pain caused by care procedures. It is therefore highly predictable and is often amenable to preventive treatment²² and administration of rescue medications.²³ Temporary exacerbations of cancer pain despite adequate baseline pain control with strong opioids make the assessment and management of cancer pain particularly critical.²⁴ The high intensity of sudden pain along with its unpredictability, rapid onset and a

negative impact on life activities and sleep quality define a 'high-rate BTcP' or 'worst BTcP' phenotype. High-rate BTcP requires intensive pain re-evaluation, frequent therapeutic adjustments and close patient follow-up.

Indeed, successful relief of breakthrough pain with careful management from baseline is crucial to improve physical and emotional function²⁵ and several aspects of health-related QoL.²⁴ Therefore, BTcP should be systematically screened in all patients with cancer who report pain, and properly treated with fast-acting fentanyl-based products, commonly referred to as transmucosal immediate-release fentanyl (TIRF).²⁶ The ESMO guidelines²⁷ recommend the use of TIRF as the first choice for the treatment of rapid-onset BTcP, limiting oral opioids, such as morphine immediate-release, to the treatment of procedural and well predictable pain. Transmucosal fentanyl provides rapid analgesia and different TIRF formulations based on innovative technologies have been developed to provide a personalized therapeutic response for patients with BTcP.^{28–31}

All patients with cancer should be screened for pain at the initial evaluation, at each subsequent contact, and whenever new therapy has initiated. The intensity of pain and the treatment outcomes should be evaluated regularly and assessed using a visual analogue scale, verbal scale, or numeric rating scale (NRS).^{32,33} Assessment of BTcP is part of an all-inclusive multidimensional evaluation of the patient and is essential for optimal cancer pain management.³³ A comprehensive pain assessment must consider the type and stage of cancer, care setting, causes of cancer pain, patient QoL, and treatment preferences. Some patients may experience multifactorial pain or pain syndromes that require complex approaches and intense analgesic schedules.³⁴

Recent studies^{35,36} have suggested a relationship between the worst BTcP phenotype and specific cancer characteristics. The aim of this narrative review is to highlight the direct correlation between high-rate BTcP and tumour characteristics or background pain types. We also report three emblematic case studies with the aim of sensitizing clinicians to the correct assessment and management of high-rate BTcP associated with certain types of cancer and to contribute significantly to preventing missed or delayed diagnosis of BTcP. The first case report involves BTcP caused by multiple bone metastases in a man with lung cancer; the second discusses BTcP in a woman with breast cancer and comorbidities; and the third discusses visceral BTcP, which is less common.

Methods

A literature search was performed in PubMed database using the key term "breakthrough pain" in the title of the

article. The search was limited to humans, adults, English language and publication years 2012–2022. Clinical trials, meta-analyses and multicentre studies were included, and we selected studies reporting both BTcP characteristics and tumour types. Some included studies were identified from the reference lists of previous narrative reviews, systematic reviews and meta-analyses on cancer pain. A manual search of the reference lists of identified papers was also performed. We used the process of creating an interpretive understanding typical of a hermeneutic review and we finally considered the studies listed in Table 1.

Review

The estimated prevalence of BTcP is approximately 70% in patients with cancer though some discrepancies persist amongst different studies.^{15,37} Although we are aware of the limitations of comparing data collected from studies with different purposes, we nevertheless observed that BTcP is more frequently associated with breast and lung cancer.

Approximately half of the patients with lung cancer reported neuropathic pain,^{38,39} approximately half had bone metastases, and approximately one-quarter reported frequent BTcP episodes.³⁴ In breast cancer, the prevalence of neuropathic pain was higher than that in other types of cancer.⁴⁰ Chronic neuropathic pain can be attributed to multiple aetiologies⁴¹; the tumour⁴² or metastases⁴³ can damage soft tissue, bones, viscera or nervous plexuses, causing chronic peripheral neuropathic pain perceived in the distribution of affected nerves.^{1,44,45} Symptoms of peripheral nerve damage include tingling, burning pain, electrical sensation, hypo-sensitivity, numbness and muscle weakness, sensorimotor deficits, and allodynia or hyperalgesia.^{41,46}

Anti-cancer treatments further contribute to the development of chronic neuropathic pain.^{47,48} Neuropathic mechanisms were predominant in postsurgical pain,¹ affecting 63% of women after mastectomy and 33% of patients after thoracotomy for lung cancer. Postsurgical pain was reported to be moderate to severe in 11–25% of cases.^{1,49,50}

Moreover, chemotherapy (i.e. taxanes, platinum-based drugs, vinca alkaloids, thalidomide and proteasome inhibitors) can induce chronic painful polyneuropathy.¹ Neuropathic pain is highly prevalent in patients who are candidates for radiotherapy for breast and lung cancer.^{51,52} However, radiotherapy can cause neuropathic pain due to cranial or peripheral nerve injury.

The most frequent clinical manifestations after radiotherapy for intracranial and extracranial metastases are

Table 1. Main studies reviewed on BTcP.

| Authors | Development method | Country/region | Enrolled patient background | Number of patients with BTcP | Sex | Mean age (years) | Spontaneous BTcP | Incident BTcP | BTcP episodes (per day) | Mean duration | Onset time | Intensity | Primary tumour localization |
|-------------------------------|--------------------------------------|----------------|-------------------------------------|------------------------------|-----------|------------------|-------------------------------------|---|-------------------------|---|-------------------------|--|--|
| Albiach et al. ^{7,6} | Survey (pain management specialists) | Spain | BTcP caused by bone metastases | 386 | Men 68.1% | 65.7 | 50% | 50% volitional 44.3% non-volitional 55.4% | 3.5±1.8 | 20.2 minutes | Rapid 61.1%; slow 38.9% | Severe 71.2%; moderate 26.7%; mild 2.1% | Lung 25.4% |
| Baek et al. ^{7,7} | Multicentre nationwide study | Korea | Cancer pain (hospitalized patients) | 177/609 | Men 59% | >65 | | | 1.95-2 | | | | Lung 25.4%; prostate 22.0% (80 % stage IV) |
| Davies et al. ² | Multicentre study | Europe | BTcP (palliative care) | 1000 | Men 51% | 62 | 41.5% 14.5% spontaneous+incident | 44% volitional 44.9% non-volitional 15.2% mixed 7.9% procedural 11.3% ND 20.5% | 3 | <10 min 15%; 10-30 min 25%; 30-60 min 23%; >60 min 37% | Time to peak 10 min | Severe 61.8%; moderate 33.7%; mild 3.6% | Gastrointestinal 26.4%; lung 17.2%; urological 16%; breast 12.5% |
| Bedard et al. ⁴ | Multicentre study | Canada | BTcP (palliative care) | 94 | Women 57% | 67 | 6.4% 28.7% spontaneous+incident | 64.9% | 2-3 | <10 min 16.6%; 10-30 min 15.2%; 30-60 min 15.2%; >60 min 50% | Time to peak 10 min | Severe 61.8%; moderate 33.7%; mild 3.6% (European data) Mean 7.8/10 (Canadian data) | Lung 21.3%; breast 21.3%; gastrointestinal 11.7%; urological 10.6% |

(Continued)

Table 1. (Continued)

| Authors | Development method | Country/region | Enrolled patient background | Number of patients with BTcP | Sex | Mean age (years) | Spontaneous BTcP | Incident BTcP | BTcP episodes (per day) | Mean duration | Onset time | Intensity | Primary tumour localization |
|----------------------------------|--|------------------------|-------------------------------|------------------------------|-------------|------------------|------------------|------------------------|-------------------------|-----------------|---------------------------------|------------------------------------|--|
| Mercadante et al. ^{7,8} | Secondary analysis of a multicentre study | | | | | | 70.5% | 29.5%; procedural 5.7% | 2.2 | Mean 52.6 min | ≤10 min 65.5%; >10 min 35.5% | 7.3 | Gastrointestinal 34.3%; pancreas 24.1%; liver 8.7%; gynaecological 7.5% |
| Shi et al. ^{3,4} | Retrospective study | China | Cancer pain (lung cancer) | 39/152 | Men 65.1% | 58 | | | | | | | Bone metastasis 44.1% |
| Husic et al. ¹⁷ | Prospective study | Bosnia and Herzegovina | Cancer pain (palliative care) | 80/433 | Men 62.6% | 62 | | | 2.41 | 16–20 min | | Mean 8.04 | Lung 33.1%; gastrointestinal 21.1%; otorhinolaryngological 15.6%; breast 15.1% |
| Mercadante et al. ²¹ | Multicentre study | Italy | BTcP (cancer at any stage) | 4056 | Men 54.8% | 64.6 | | Predictable 33% | 2.5 | 43 min | | Mean 7.5 | Lung 24.0%; breast 11.3%; gastrointestinal 25.4%; prostate 4.9% |
| Magnani et al. ²² | Prospective, observational and cross-sectional study | Italy | Cancer pain (palliative care) | 149/1180 | Women 55.7% | 71.5 | | | | 15–30 min 53.0% | 0–10 min 51.0%; 10–20 min 44.3% | 1–4 (34.2) 5–6 (43.6) ≥7–10 (22.1) | Lung cancer 24.8%; gastrointestinal 18.8%; urological 11.4%; breast 10.1%; multiple metastasis 65.1%; bone metastasis 6.0% |
| Mercadante et al. ^{7,9} | Secondary analysis of IOPS-MS multicentre study | Italy | Visceral cancer pain | 414/470 | Women 50.5% | 65 | 70% | 21%; procedural 9% | 2.7 | | | | Lung 33.1%; gastrointestinal 13.0%; breast/ gynaecological 7.8% |

(Continued)

Table 1. (Continued)

| Authors | Development method | Country/region | Enrolled patient background | Number of patients with BTcP | Sex | Mean age (years) | Spontaneous BTcP | Incident BTcP | BTcP episodes (per day) | Mean duration | Onset time | Intensity | Primary tumour localization |
|----------------------------|---|----------------|---|------------------------------|-------------|------------------|------------------|---------------|-------------------------|---------------|------------|------------|--|
| Cuomo et al. ²⁴ | Clinical study | Italy | BTcP (solid tumours at any stage) | 154 | Men 55.8% | 63.5 | 71.1% | 72.7% | >30 min, 73.9% | 8.24 | | | Gastrointestinal 21.6%; breast 17.6%; otorhinolaryngological 15.7%; haematological 15.7%; gynaecological 11.8% |
| Brant et al. ⁶⁰ | Prospective, quantitative, longitudinal, single-arm pilot study | USA | BTcP (advanced cancer) | 51 | Women 62.7% | 56.3 | | | | | | ≥7 (84.1%) | Lung 29.95%; colorectal 11.15%; otorhinolaryngological 7.14%; stage III or IV bone metastasis 31.1% |
| Fan et al. ⁶¹ | Retrospective cross-sectional analysis | China | BTcP (cancer stage III or IV, 55.8% metastatic) | 428/798 | Men 56.6% | 56.7 | | | | | | | |

BTcP, breakthrough cancer pain; IOPS-MS, Italian Oncologic Pain multisetting Multicentric Survey; ND, not determined.

cranial neuralgias after radiotherapy for intracranial and extracranial metastases⁵³ and painful brachial plexopathy in breast and apical lung cancer. In addition, stereotaxic body radiotherapy for apical lung cancer should improve the risk of brachial plexopathy.⁵⁴

Finally, lung, breast and prostate cancers account for more than 50% of cases of metastatic spinal cord compression⁵⁵ caused by prolonged direct pressure from the tumour mass or by tumour-induced pathological collapse of the vertebral bone metastases.⁵⁶ The most common location for cord compression is the thoracic spine, followed by the lumbosacral spine and the cervical level.⁴³ Patients with epidural spinal cord compression experience back pain, weakness, sensory changes and autonomic dysfunction; therefore, prompt diagnosis is essential.

Neuropathic pain is associated with poor outcomes in cancer pain control⁵⁷ with greater analgesic requirements and disability.⁴⁴ When associated with BTcP, neuropathic pain causes not only an overall impairment of health-related QoL but also a substantial increase in healthcare costs.⁵⁸

Patients with cancer often complain of pain caused by bone metastases, which are common in breast, prostate and lung cancer.^{59–61} Post-mortem studies have estimated that 70–90% of patients with breast or prostate cancer have evidence of bone metastasis.⁶² The most common sites of metastases are the vertebrae, pelvis, long bones, and ribs⁶³ and innocuous movement, bumps or falls may result in painful pathological fractures,¹ which might reduce mobility and increase anxiety, significantly worsening QoL.⁶⁴ Many breakthrough pain episodes of greater intensity in the advanced stages of cancer are due to bone pain caused by metastasis¹⁷ and require additional proper therapy. Albiach et al.⁷⁶ collected data from patients with metastatic bone disease and BTcP and demonstrated that primary cancer was mainly localized in the lungs and prostate (85 out of 386 patients or 22%), and BTcP occurred spontaneously and suddenly with high pain intensity in 70.6% of cases.

Mercadante et al.⁶⁵ conducted a secondary analysis of the IOPS-MS study including 4056 patients with BTcP and showed that patients with lung cancer had higher levels of background pain, higher BTcP intensity, and greater interference with daily activities. The main causes of BTcP were cough and movement related to bone metastases. Shi et al.³⁴ reported moderate-to-severe chronic neuropathic pain in 46.7% of 152 patients with lung cancer and BTcP in 25.7%, mostly associated with a high intensity of background pain. Cuomo et al.²⁴ and Brant et al.⁸⁰ found high percentages (70% and 71%,

respectively) of spontaneous BTcP, and the episodes of BTcP had a high average intensity (NRS ≥ 7).

A recent univariate analysis³⁶ based on the IOPS-MS study¹⁵ analyzed data from 2671 patients with non-predictable BTcP, resulting in the identification of four BTcP phenotypes. The worst unpredictable BTcP had a fast onset time of <10 minutes and was mainly managed with TIRF.²⁶ This phenotype is significantly associated with younger age and lung cancer. Pantano et al.³⁵ published a similar study aimed at identifying novel sub-types of BTcP by using unsupervised learning algorithms. The study demonstrated that specific BTcP clusters, each associated with specific clinical features, were linked to therapy satisfaction or dissatisfaction. Finally, approximately 55% of patients with abdominal cancer pain developed BTcP episodes, with a higher percentage (90%) of patients with previous uncontrolled background pain.⁶⁶

Mercadante et al.,⁶⁶ in their secondary analysis of the IOPS-MS study, observed that postprandial BTcP in visceral cancer pain is mainly associated with pancreatic cancer. In these patients, BTcP showed a lower intensity (mean NRS 6.9), faster onset and shorter duration (mean 45.8 minutes) in comparison with other causes of predictable BTcP and unpredictable BTcP.

Prevalence data on pancreatic cancer-related pain vary from 47% to 63% at diagnosis and 82% in advanced-stage cancer in patients referred to palliative care, with a positive correlation between pain and disease progression or poor outcomes. Patients with pancreatic cancer reported high intensity cancer pain and severe interference with activities of daily living.^{67–69} The most common sites of metastatic disease are peritoneum, liver and lung.⁶⁹ Abdominal pain is usually referred to as lower mid-back pain and is accompanied by weight loss and sometimes jaundice. Local pain may be related to intraluminal activation of pancreatic enzymes and malignant obstruction and distention of the pancreatobiliary tree, whereas anterior mass progression may cause small bowel distension and severe abdominal or intestinal colic pain, usually accompanied by nausea and vomiting.⁶⁹ Involvement of the peritoneum, abdominal wall, retroperitoneal tissues, and both intra-pancreatic and extra pancreatic nerve plexuses, including the celiac plexus, determines mixed nociceptive and neuropathic pain.^{1,66,69}

Despite the World Health Organization guidelines regarding mild-to-moderate cancer pain treatment, only 40–49.6% of patients with pain due to pancreatic cancer receive a combination of opioids, adjuvant analgesic drugs and TIRF as the first choice for the treatment of unpredictable and rapid-onset BTcP.^{41,57,68,70}

Case reports

Three clinical reports from real-life experiences in cancer pain management have been described with the intent of exemplifying pain management in complex cases. In these case series, the worst BTcP phenotypes were correlated with specific cancer characteristics and background pain types. All the data referring to the patients were published anonymously without any details allowing re-identification of the patient, and in accordance with the World Medical Association Declaration of Helsinki.

Case report 1

A 56-year-old male patient complained of dry cough, chest tightness, and cervical-dorsal pain for 2 months due to C3 and T1 vertebral body metastases. A contrast-enhanced chest CT scan demonstrated an 18-mm abnormal mass in the left lung, a solid left hilar mass and several bone metastases confirmed by ¹⁸F-fluoro-2-deoxyglucose (FDG)-fluorodeoxyglucose positron emission (PET)/computed tomography (CT).

Stage IV lung adenocarcinoma was diagnosed. Genetic tests using next-generation sequencing of the lung lesion biopsy revealed *KRAS* G12C mutation, whereas other tested driver genes were absent. PDL1 expression was 10%. After active discussions, a multidisciplinary team (including oncologist, pathologist, respiratory physician, thoracic surgeons, radiologist and radiotherapist) agreed to treat the patient with chemotherapy plus immunotherapy (carboplatin plus pemetrexed plus pembrolizumab) and radiotherapy (8 Gy in a single fraction) on the bone metastases at risk for fracture and pain (C3, T1 and sacrum).

The patient experienced severe pain (NRS >7) for most of the day, causing reduced daily activity, sadness, low concentration, and a significant decrease in appetite and time spent sleeping. Paracetamol 1000 mg three times/day was not enough for a real benefit, so an oral controlled-release formulation of oxycodone was added (at a dose of 5 mg every 12 h gradually increased to 20 mg every 12 h), without side-effects related to opioids. Fairly good control of the baseline pain was achieved (NRS 2), but the patient reported sudden, severe and short-lasting pain, two to three times per day, in the neck and sometimes in the left leg when walking. A sub-lingual formulation of transmucosal immediate-release fentanyl at a dose of 133 µg was added for the BTcP episodes. Since no adequate analgesia was obtained within 15–30 minutes of administration of a single tablet, a supplemental 133 µg tablet was administered. BTcP episodes were controlled with 267 µg of fentanyl sub-

lingual tablets. The recommendation was to use one sub-lingual tablet (267 µg) no more than four times per day.

After three cycles of chemo-immunotherapy, evaluation of the therapeutic effect presented a partial response based on the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).

As a result of our prescription, the patient had strong relief of pain with optimal pain control, and there was also an improvement in quality of life and daily activities.

Case report 2

The patient was a 63-year-old woman with chronic kidney disease, type 2 diabetes and dyslipidaemia. In 2001, at the age of 43 years, she underwent left super external quadrantectomy and ipsilateral axillary lymphadenectomy for breast cancer (invasive ductal carcinoma, grade 2). The patient received standard radiotherapy after surgery, adjuvant therapy with six cycles of cyclophosphamide-methotrexate-5 fluorouracil, and triptorelin combined with tamoxifen for 5 years. In 2018, following the occurrence of left leg pain, clinical examination and whole-body ¹⁸FDG-PET/CT scans revealed high FDG uptake in the vertebral (T4, T5, L1, L3, L5, S) scapulae, right IV rib, left femur and lymph nodes from the left supraclavicular and ilio-pulmonary areas. Supraclavicular lymph node biopsy confirmed metastasis of infiltrating ductal carcinoma, and letrozole (2.5 mg once daily) and denosumab (120 mg IV every 4 weeks) were administered. Magnetic resonance imaging (MRI) in the T1, T2 and STIR sequences of the spine excluded the presence of vertebral collapse. Radiotherapy on T10–S1 (25 Gy) and the left femur (30 Gy) was performed for palliative, analgesic and decompressive purposes and for the prevention of severe bone events.

The patient complained of moderate-to-severe pain (mean NRS 6–7) throughout the day and night, causing a reduction in sleep quality and duration. The pain was localized mainly in the lumbar spine and left hip and increased when sitting or standing, forcing the use of walking aids. She reported only partial benefit from paracetamol/codeine 500/30 (two tablets three times a day) and moderate benefit with the use of oral ketorolac (up to 40 mg/day), as needed. In view of chronic kidney disease stage 3, a buprenorphine transdermal system of 35 µg/h was applied and replaced every 96 hours (twice a week at regular intervals). The dosage was gradually increased over the weeks to 52.5 µg/h, and paracetamol was continued at a dose of 3 g/day. The patient was advised to complete a daily pain diary.

At the next control, the patient reported a reduction in baseline pain intensity. Average NRS was 5, but the pain diary showed several peaks of very intense pain (NRS 8–9), of variable duration, both spontaneous and mainly triggered by movement. The high frequency of these pain peaks and their increase near the transdermal patch replacement suggested that background pain was still not fully controlled. Therefore, the dosage of transdermal buprenorphine was increased to 70 µg/h, and naldemedine 200 µg tablets (once daily) was associated with the control of opioid-induced constipation. The subsequent pain diary showed the clear presence of BTcP episodes, for which 133 µg sublingual fentanyl was recommended, advising the patient to take it 5 minutes before triggering activities (i.e. standing or walking) or immediately at the onset of the unpredictable pain flair, and in any case no more than four times a day.

At the next telemedicine clinical follow-up, the patient reported good background pain control (NRS 3) and two to three BTcP episodes per day, well managed with sublingual fentanyl, which was increased to 267 µg.

Case report 3

A 56-year-old male patient was treated for abdominal pain and upper abdominal heaviness for approximately 3 months, with over-the-counter pain medication (mainly paracetamol up to 3 g/day or non-steroidal anti-inflammatory drugs) and weak opioids (tramadol as needed), which allowed unsatisfactory pain relief. Imaging studies showed a 3.5-cm pancreatic adenocarcinoma (cT2N0) that was borderline resectable. Neoadjuvant chemotherapy with the mFOLFIRINOX regimen (irinotecan/oxaliplatin/leucovorin/5-fluorouracil) was started. The patient reported visceral pain in the upper abdominal area and under the ribs, sometimes spreading to the back and worsening after eating or drinking. The pain intensity was moderate to severe (NRS 5–6).

The patient was started with transdermal fentanyl 12 µg/h subsequently increased to 25 µg/h due to nausea and vomiting that limited the regular intake of oral therapy.

After 2 weeks, the patient reported very good control of his pain (NRS <3) for most of the day but complained of two to three episodes per day of unpredictable flares of severe pain (NRS 7–8) with short duration, occasionally associated with big meals or defecation.

Sublingual fentanyl 133 µg up to four times a day was prescribed for BTcP, and constipation was better managed with a peripherally acting µ-opioid receptor antagonist (naloxegol 25 mg once a day).

Due to depressed mood and sleep disorders, after psychological consultation, the multidisciplinary team

agreed to include duloxetine 30 mg once daily in the morning in order to treat symptoms of reactive depression secondary to cancer and chronic pain with a neuropathic component. Pain was then well controlled, and the patient started working again almost at full capacity and had an active family and social life.

After four cycles of chemotherapy, the patient started radiation therapy with concomitant use of capecitabine. Treatment showed a decrease in tumour diameter (1.5 cm) yet it was still in contact with the superior mesenteric artery. Pain decreased and opioid therapy was gradually discontinued. The patient was placed under observation, and new staging studies are expected.

Future perspectives

As cancer pain requires complex and multidisciplinary treatment modalities, patient management should be improved through technological advances. Telemedicine, as a remote system, could be seen as an opportunity for access to care and ongoing support as well as an opportunity to achieve the challenging goal of personalized cancer pain management.^{71,72} Hybrid models appear to be a valid, modern, tailored approach to cancer pain management, improving patient satisfaction and healthcare costs, combining face-to-face visits and a scheduled remote follow-up programme with hospital readmissions as needed.⁷¹ The implementation of telemedicine must be supported by the development of information technology infrastructure⁷¹ and the training of patients and caregivers in the use of the telemedicine system.⁷³

Additionally, new tools such as artificial intelligence (AI) and machine learning will soon become critical and indispensable resources that can improve care pathways, identify urgent activities and provide an appropriate response to the specific needs of the patient.^{73,74} AI is also able to optimize drug discovery processes, their commercialization and associated costs.⁷⁵ This, combined with innovative drug delivery technologies, will allow improved customization of cancer pain therapy.

Finally, the implementation of AI-based applications could be useful for the future development of clinical trials. Recent studies have offered a novel approach to study BTcP through AI-based patient enrolment and stratification.^{35,36}

Conclusion

Cancer pain requires careful comprehensive patient evaluation, individualized assessment and treatment by a trained multidisciplinary team. Specific treatment

must be planned for each patient, considering comorbidities and drug side-effects. Cancer pain intensity and the use of high doses of opioids are independent risk factors for poor prognosis and shorter survival in patients with cancer. Conversely, effective management of cancer-related pain improves the patient-perceived value of cancer treatment.

Alongside telemedicine, AI could represent a promising scenario, enabling physicians to make effective and data-driven decisions in a real-life context. The available evidence suggests that the worst BTcP phenotypes can be correlated with specific cancer characteristics

or background pain types. BTcP should be systematically assessed in all patients with cancer. When background pain is controlled by strong opioids, BTcP must be properly treated with TIRF, limiting the use of immediate-release or intravenous morphine to selected cases according to BTcP characteristics, patient requirements and safety.

A challenge for BTcP management is the implementation of novel approaches, which should provide guidance for the future clinical practice of healthcare professionals involved in the multidisciplinary and tailored management of cancer pain.

Contributions: AB, FC and DN wrote the clinical case series. AC supervised the project. All authors read and approved the final manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: AB and FC received honoraria from Angelini Pharma S.p.A. AC and DN declare no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: <https://www.drugsincontext.com/wp-content/uploads/2023/02/dic.2022-11-1-COI.pdf>

Acknowledgements: The authors would like to thank Dr Claudia Laterza, on behalf of Content Ed Net, for medical writing and editorial assistance.

Funding declaration: This initiative was carried out with the unconditional contribution of Angelini Pharma S.p.A.

Copyright: Copyright © 2023 Cuomo A, Boutis A, Colonese F, Nocerino D. Published by *Drugs in Context* under Creative Commons License Deed CC BY NC ND 4.0, which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2023 Cuomo A, Boutis A, Colonese F, Nocerino D. <https://doi.org/10.7573/dic.2022-11-1>. Published by *Drugs in Context* under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: <https://www.drugsincontext.com/high-rate-breakthrough-cancer-pain-and-tumour-characteristics-literature-review-and-case-series>

Correspondence: Arturo Cuomo, IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy. Email: a.cuomo@istitutotumori.na.it

Provenance: Submitted; externally peer reviewed.

Submitted: 2 November 2022; **Accepted:** 8 February 2023; **Published:** 10 March 2023.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: 6 Green Lane Business Park, 238 Green Lane, New Eltham, London, SE9 3TL, UK.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

References

1. Bennett MI, Kaasa S, Barke A, Korwisi B, Rief W, Treede RD. The IASP classification of chronic pain for ICD-11: chronic cancer-related pain. *Pain*. 2019;160(1):38–44. <https://doi.org/10.1097/j.pain.0000000000001363>
2. Bernstein LR. A pragmatic, general definition of pain. 2020. <https://doi.org/10.1097/PR9.0000000000000813>
3. Deng D, Fu L, Zhao YX, et al. The relationship between cancer pain and quality of life in patients newly admitted to Wuhan Hospice Center of China. *Am J Hosp Palliat Care*. 2012;29(1):53–59. <https://doi.org/10.1177/1049909111418636>
4. Bedard G, Davies A, McDonald R, et al. Breakthrough cancer pain: a comparison of surveys with European and Canadian patients. *Support Care Cancer*. 2015;23(3):791–796. <https://doi.org/10.1007/s00520-014-2426-6>
5. Matsumura C, Yamada M, Jimaru Y, Ueno R, Takahashi K, Yano Y. Relationship between pain scores and EORTC QLQ-C15-PAL scores in outpatients with cancer pain receiving opioid therapy. *Biol Pharm Bull*. 2021;44(3):357–362. <https://doi.org/10.1248/bpb.b20-00626>
6. Neufeld NJ, Elnahal SM, Alvarez RH. Cancer pain: a review of epidemiology, clinical quality and value impact. *Future Oncol*. 2017;13(9):833–841. <https://doi.org/10.2217/fo-2016-0423>
7. van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. *J Pain Symptom Manage*. 2016;51(6):1070–1090.e9. <https://doi.org/10.1016/j.jpainsymman.2015.12.340>
8. Rodriguez C, Ji M, Wang HL, Padhya T, McMillan SC. Cancer pain and quality of life. *J Hosp Palliat Nurs*. 2019;21(2):116–123. <https://doi.org/10.1097/NJH.0000000000000507>
9. Lin J, Hsieh R, Chen J, et al. Satisfaction with pain management and impact of pain on quality of life in cancer patients. *Asia Pac J Clin Oncol*. 2020;16(2):e91–e98. <https://doi.org/10.1111/ajco.13095>
10. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. *Pain*. 1999;81(1):129–134. [https://doi.org/10.1016/S0304-3959\(99\)00006-8](https://doi.org/10.1016/S0304-3959(99)00006-8)
11. Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. *J Pain Symptom Manag*. 2014;47(1):57–76. <https://doi.org/10.1016/j.jpainsymman.2013.02.015>
12. Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. *J Pain Symptom Manag*. 2013;46(5):619–628. <https://doi.org/10.1016/j.jpainsymman.2012.12.009>
13. Raj SX, Thronaes M, Brunelli C, Hjermstad MJ, Klepstad P, Kaasa S. A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic. *Support Care Cancer*. 2014;22(7):1965–1971. <https://doi.org/10.1007/s00520-014-2178-3>
14. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. *Eur J Pain*. 2009;13(4):331–338. <https://doi.org/10.1016/j.ejpain.2008.06.014>
15. Mercadante S, Lazzari M, Reale C, et al. Italian Oncological Pain Survey (IOPS). *Clin J Pain*. 2015;31(3):214–221. <https://doi.org/10.1097/AJP.0000000000000161>
16. Vellucci R, Mediati RD, Gasperoni S, Mammucari M, Marinangeli F, Romualdi P. Assessment and treatment of breakthrough cancer pain: from theory to clinical practice. *J Pain Res*. 2017;10:2147–2155. <https://doi.org/10.2147/JPR.S135807>
17. Husic S, Imamovic S, Matic S, Sukalo A. Characteristics and treatment of breakthrough pain (BTcP) in palliative care. *Med Arch*. 2017;71(4):246–250. <https://doi.org/10.5455/medarh.2017.71.246-250>
18. Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. In: Zeppetella G, ed. *Cochrane Database Syst Rev*. 2013;10:CD004311. <https://doi.org/10.1002/14651858.CD004311.pub3>
19. Zucco F, Bonezzi C, Fornasari D. Breakthrough Cancer Pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy. *Adv Ther*. 2014;31(7):657–682. <https://doi.org/10.1007/s12325-014-0130-z>
20. Mercadante S, Cuomo A. Breakthrough cancer pain: ten commandments. *Value Health*. 2016;19(5):531–536. <https://doi.org/10.1016/j.jval.2016.03.002>
21. Mercadante S, Marchetti P, Cuomo A, et al. Breakthrough cancer pain: preliminary data of the Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS). *Adv Ther*. 2017;34(1):120–135. <https://doi.org/10.1007/s12325-016-0440-4>
22. Magnani C, Giannarelli D, Calvieri A, et al. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer. *Postgrad Med J*. 2018. <https://doi.org/10.1136/postgradmedj-2018-135659>

23. Bossi P, Antonuzzo A, Armento G, et al. What to do and what not to do in the management of cancer pain: a physician survey and expert recommendations. *Cancer Manag Res*. 2021;13:5203–5210. <https://doi.org/10.2147/CMAR.S310651>
24. Cuomo A, Cascella M, Forte CA, et al. Careful breakthrough cancer pain treatment through rapid-onset transmucosal fentanyl improves the quality of life in cancer patients: results from the BEST multicenter study. *J Clin Med*. 2020;9(4):1003. <https://doi.org/10.3390/jcm9041003>
25. Matsumura C, Yamada M, Jimaru Y, Ueno R, Takahashi K, Yano Y. Relationship between pain scores and EORTC QLQ-C15-PAL scores in outpatients with cancer pain receiving opioid therapy. *Biol Pharm Bull*. 2021;44(3):357–362. <https://doi.org/10.1248/bpb.b20-00626>
26. US FDA. Transmucosal Immediate-Release Fentanyl (TIRF) Medicines. <https://www.fda.gov/drugs/information-drug-class/transmucosal-immediate-release-fentanyl-tirf-medicines>. Accessed September 3, 2022.
27. Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2018;29:iv166–iv191. <https://doi.org/10.1093/annonc/mdy152>
28. Zeppetella G. Breakthrough pain in cancer patients. *Clin Oncol*. 2011;23(6):393–398. <https://doi.org/10.1016/j.clon.2010.12.002>
29. Mercadante S. Pharmacotherapy for breakthrough cancer pain. *Drugs*. 2012;72(2):181–190. <https://doi.org/10.2165/11597260-000000000-00000>
30. Mercadante S. Treating breakthrough pain in oncology. *Expert Rev Anticancer Ther*. 2018;18(5):445–449. <https://doi.org/10.1080/14737140.2018.1443813>
31. Janknegt R, van den Beuken M, Schiere S, et al. Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis. *Eur J Hosp Pharm*. 2018;25(3):e2. <https://doi.org/10.1136/ejhpharm-2016-001127>
32. Haefeli M, Elfering A. Pain assessment. *Eur Spine J*. 2006;15(S1):S17–S24. <https://doi.org/10.1007/s00586-005-1044-x>
33. Marinangeli F, Saetta A, Lugini A. Current management of cancer pain in Italy: expert opinion paper. *Open Med*. 2021;17(1):34–45. <https://doi.org/10.1515/med-2021-0393>
34. Shi L, Liu Y, He H, Wang C, Li H, Wang N. Characteristics and prognostic factors for pain management in 152 patients with lung cancer. *Patient Prefer Adherence*. 2016;10:571–577. <https://doi.org/10.2147/PPA.S103276>
35. Pantano F, Manca P, Armento G, et al. Breakthrough cancer pain clinical features and differential opioids response: a machine learning approach in patients with cancer from the IOPS-MS study. *JCO Precis Oncol*. 2020;(4):1339–1349. <https://doi.org/10.1200/PO.20.00158>
36. Cascella M, Crispo A, Esposito G, et al. Multidimensional statistical technique for interpreting the spontaneous breakthrough cancer pain phenomenon. A secondary analysis from the IOPS-MS study. *Cancers*. 2021;13(16):4018. <https://doi.org/10.3390/cancers13164018>
37. Mercadante S. Breakthrough pain in cancer patients. *Curr Opin Anaesthesiol*. 2015;28(5):559–564. <https://doi.org/10.1097/ACO.0000000000000224>
38. Gül ŞK, Tepetam H, Gül HL. Duloxetine and pregabalin in neuropathic pain of lung cancer patients. *Brain Behav*. 2020;10(3). <https://doi.org/10.1002/brb3.1527>
39. Zylla D, Kuskowski MA, Gupta K, Gupta P. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. *Br J Anaesth*. 2014;113:i109–i116. <https://doi.org/10.1093/bja/aeu351>
40. Ilhan E, Chee E, Hush J, Moloney N. The prevalence of neuropathic pain is high after treatment for breast cancer: a systematic review. *Pain*. 2017;158(11):2082–2091. <https://doi.org/10.1097/j.pain.0000000000001004>
41. Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. *Pain*. 2019;160(1):53–59. <https://doi.org/10.1097/j.pain.0000000000001365>
42. Antoine JC, Camdessanché JP. Peripheral nervous system involvement in patients with cancer. *Lancet Neurol*. 2007;6(1):75–86. [https://doi.org/10.1016/S1474-4422\(06\)70679-2](https://doi.org/10.1016/S1474-4422(06)70679-2)
43. Mendez JS, DeAngelis LM. Metastatic complications of cancer involving the central and peripheral nervous systems. *Neurol Clin*. 2018;36(3):579–598. <https://doi.org/10.1016/j.ncl.2018.04.011>
44. Shkodra M, Brunelli C, Zecca E, et al. Neuropathic pain: clinical classification and assessment in patients with pain due to cancer. *Pain*. 2021;162(3):866–874. <https://doi.org/10.1097/j.pain.0000000000002076>
45. Hochberg U, Elgueta MF, Perez J. Interventional analgesic management of lung cancer pain. *Front Oncol*. 2017;7:17. <https://doi.org/10.3389/fonc.2017.00017>
46. Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. *Cochrane Database Syst Rev*. 2019;1:CD007076. <https://doi.org/10.1002/14651858.CD007076.pub3>
47. Wang K, Yee C, Tam S, et al. Prevalence of pain in patients with breast cancer post-treatment: a systematic review. *Breast*. 2018;42:113–127. <https://doi.org/10.1016/j.breast.2018.08.105>

48. Mercadante S, Vitrano V. Pain in patients with lung cancer: pathophysiology and treatment. *Lung Cancer*. 2010;68(1):10–15. <https://doi.org/10.1016/j.lungcan.2009.11.004>
49. Schug SA, Lavand'homme P, Barke A, Korwisi B, Rief W, Treede RD. The IASP classification of chronic pain for ICD-11: chronic postsurgical or posttraumatic pain. *Pain*. 2019;160(1):45–52. <https://doi.org/10.1097/j.pain.0000000000001413>
50. Chappell AG, Yuksel S, Sasson DC, Wescott AB, Connor LM, Ellis MF. Post-mastectomy pain syndrome: an up-to-date review of treatment outcomes. *JPRAS Open*. 2021;30:97–109. <https://doi.org/10.1016/j.jptra.2021.07.006>
51. Mañas A, Monroy JL, Ramos AA, et al. Prevalence of neuropathic pain in radiotherapy oncology units. *Int J Radiat Oncol Biol Phys*. 2011;81(2):511–520. <https://doi.org/10.1016/j.ijrobp.2010.05.047>
52. Lam E, Wong G, Zhang L, et al. Self-reported pain in breast cancer patients receiving adjuvant radiotherapy. *Support Care Cancer*. 2021;29(1):155–167. <https://doi.org/10.1007/s00520-020-05462-5>
53. Delanian S, Lefaix JL, Pradat PF. Radiation-induced neuropathy in cancer survivors. *Radiother Oncol*. 2012;105(3):273–282. <https://doi.org/10.1016/j.radonc.2012.10.012>
54. Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. *Radiother Oncol*. 2009;93(3):408–413. <https://doi.org/10.1016/j.radonc.2009.04.018>
55. Nair C, Panikkar S, Ray A. How not to miss metastatic spinal cord compression. *Br J Gen Pract*. 2014;64(626):e596–e598. <https://doi.org/10.3399/bjgp14X681589>
56. Al-Qurainy R, Collis E. Metastatic spinal cord compression: diagnosis and management. *BMJ*. 2016;353:i2539. <https://doi.org/10.1136/bmj.i2539>
57. Rayment C, Hjermsstad MJ, Aass N, et al. Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative–Computerised Symptom Assessment study. *Palliat Med*. 2013;27(8):714–721. <https://doi.org/10.1177/0269216312464408>
58. Madariaga Muñoz MC, Villegas Estévez F, Jiménez López AJ, Cabezón Álvarez A, Soler López B. Evaluation of quality of life and satisfaction of patients with neuropathic pain and breakthrough pain: economic impact based on quality of life. *Pain Res Treat*. 2018;2018:1–8. <https://doi.org/10.1155/2018/5394021>
59. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res*. 2006;12(20):6243s–6249s. <https://doi.org/10.1158/1078-0432.CCR-06-0931>
60. Li S, Peng Y, Weinhandl ED, et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. *Clin Epidemiol*. 2012;4(1):87–93. <https://doi.org/10.2147/CLEP.S28339>
61. Smith HS, Mohsin I. Painful Boney metastases. *Korean J Pain*. 2013;26(3):223–241. <https://doi.org/10.3344/kjp.2013.26.3.223>
62. Huang JF, Shen J, Li X, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. *Ann Transl Med*. 2020;8(7):482–482. <https://doi.org/10.21037/atm.2020.03.55>
63. Kane CM, Hoskin P, Bennett MI. Cancer induced bone pain. *BMJ*. 2015;350:h315. <https://doi.org/10.1136/bmj.h315>
64. Walker MS, Miller PJE, Namjoshi M, Houts AC, Stepanski EJ, Schwartzberg LS. Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases. *J Med Econ*. 2013;16(1):179–189. <https://doi.org/10.3111/13696998.2012.737883>
65. Mercadante S, Masedu F, Valenti M, Aielli F. Breakthrough pain in patients with lung cancer. A secondary analysis of IOPS MS study. *J Clin Med*. 2020;9(5):1337. <https://doi.org/10.3390/jcm9051337>
66. Mercadante S, Adile C, Giarratano A, Casuccio A. Breakthrough pain in patients with abdominal cancer pain. *Clin J Pain*. 2014;30(6):510–514. <https://doi.org/10.1097/AJP.0000000000000004>
67. Ceyhan GO, Michalski CW, Demir IE, Müller MW, Friess H. Pancreatic pain. *Best Pract Res Clin Gastroenterol*. 2008;22(1):31–44. <https://doi.org/10.1016/j.bpg.2007.10.016>
68. Oh SY, Shin SW, Koh SJ, et al. Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients. *Support Care Cancer*. 2017;25(12):3759–3767. <https://doi.org/10.1007/s00520-017-3806-5>
69. Carvajal G. Pancreatic cancer related pain: review of pathophysiology and intrathecal drug delivery systems for pain management. *Pain Physician*. 2021;24(5):E583–E594.
70. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. *Lancet Oncol*. 2012;13(2):e58–e68. [https://doi.org/10.1016/S1470-2045\(12\)70040-2](https://doi.org/10.1016/S1470-2045(12)70040-2)
71. Cascella M, Coluccia S, Grizzuti M, et al. Satisfaction with telemedicine for cancer pain management: a model of care and cross-sectional patient satisfaction study. *Curr Oncol*. 2022;29(8):5566–5578. <https://doi.org/10.3390/curroncol29080439>

72. Cascella M, Schiavo D, Grizzuti M, et al. Implementation of a hybrid care model for telemedicine-based cancer pain management at the Cancer Center of Naples, Italy: a cohort study. *In Vivo*. 2023;37(1):385–392. <https://doi.org/10.21873/invivo.13090>
73. Cascella M, Coluccia S, Monaco F, et al. Different machine learning approaches for implementing telehealth-based cancer pain management strategies. *J Clin Med*. 2022;11(18):5484. <https://doi.org/10.3390/jcm11185484>
74. Bellini V, Cascella M, Cutugno F, et al. Understanding basic principles of artificial intelligence: a practical guide for intensivists. *Acta Biomed*. 2022;93(5):e2022297. <https://doi.org/10.23750/abm.v93i5.13626>
75. Gallego V, Naveiro R, Roca C, Ríos Insua D, Campillo NE. AI in drug development: a multidisciplinary perspective. *Mol Divers*. 2021;25(3):1461–1479. <https://doi.org/10.1007/s11030-021-10266-8>
76. Ferrer Albiach C, Villegas Estévez F, López Alarcón MD, et al. Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain. *J Pain Res*. 2019;12:2125–2135. <https://doi.org/10.2147/JPR.S194881>
77. Bæk SK, Kim DY, Kang SY, Sym SJ, Kim YS, Lee JY. A Korean Nationwide survey for breakthrough cancer pain in an inpatient setting. *Cancer Res Treat*. 2016;48(2):768–774. <https://doi.org/10.4143/crt.2015.087>
78. Mercadante S, Adile C, Masedu F, Marchetti P, Costanzi A, Aielli F. Factors influencing the use of opioids for breakthrough cancer pain: a secondary analysis of the IOPS-MS study. *Eur J Pain*. 2019;23(4):719–726. <https://doi.org/10.1002/ejp.1339>
79. Mercadante S, Adile C, Masedu F, Valenti M, Aielli F. Breakthrough cancer pain in patients with abdominal visceral cancer pain. *J Pain Symptom Manag*. 2019;57(5):966–970. <https://doi.org/10.1016/j.jpainsymman.2019.02.014>
80. Brant J, Wujcik D, Dudley WN, et al. Shared decision-making in managing breakthrough cancer pain in patients with advanced cancer. *J Adv Pract Oncol*. 2022;13(1):19–29. <https://doi.org/10.6004/jadpro.2022.13.1.2>
81. Fan R, Li X, Yang S, et al. Retrospective observational study on the characteristics of pain and associated factors of breakthrough pain in advanced cancer patients. *Pain Res Manag*. 2022;2022:11. <https://doi.org/10.1155/2022/8943292>